Compare LGND & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGND | GRFS |
|---|---|---|
| Founded | 1987 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.2B |
| IPO Year | 1997 | 2008 |
| Metric | LGND | GRFS |
|---|---|---|
| Price | $316.86 | $8.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $361.27 | $10.37 |
| AVG Volume (30 Days) | 185.1K | ★ 735.9K |
| Earning Date | 10-29-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 3.13% |
| EPS Growth | ★ 2886.36 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $141,102,000.00 | N/A |
| Revenue This Year | $8.82 | $1.89 |
| Revenue Next Year | $31.67 | $6.20 |
| P/E Ratio | $1,019.68 | ★ $18.67 |
| Revenue Growth | ★ 29.48 | N/A |
| 52 Week Low | $175.89 | $6.96 |
| 52 Week High | $326.63 | $9.77 |
| Indicator | LGND | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 73.23 |
| Support Level | $277.97 | $7.18 |
| Resistance Level | $319.83 | $8.83 |
| Average True Range (ATR) | 11.45 | 0.25 |
| MACD | -0.28 | 0.07 |
| Stochastic Oscillator | 67.94 | 91.35 |
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.